Get the Daily Brief
Latest Biotech News
TrumpRx rollout draws scrutiny: discounts limited, generics undercut claims
The White House launched TrumpRx, an online drug‑pricing portal offering discounted cash prices on a selected list of medicines, but early analysis shows limited benefit for many insured patients....
Biotech IPO surge: Eikon prices big debut as market appetite returns
Biotech public markets saw a notable week as multiple companies priced IPOs, led by Eikon Therapeutics’ upsized offering. Eikon sold shares to raise roughly $381 million to advance a cancer...
Adaptive projects MRD business growth as ClonoSeq adoption climbs
Adaptive Biotechnologies issued upbeat 2026 guidance, forecasting MRD (minimal residual disease) revenue growth of at least 20% as adoption of its ClonoSeq assay expands across hematologic...
Phage‑antibiotic combo clears resistant peritonitis in preclinical model
A Nature Communications study led by Yang, Wu, and Jiang demonstrated that combining bacteriophages with conventional antibiotics eradicated refractory peritoneal dialysis–related peritonitis...
Two studies map immune‑metabolic levers in pancreatic cancer
Two independent preclinical studies revealed complementary immune and metabolic mechanisms that may be leveraged in pancreatic ductal adenocarcinoma (PDAC). One team reported that targeted...
CRISPR tactic exploits oncogene amplification to target tumors
A consortium from the Spanish National Cancer Research Centre (CNIO) and CIEMAT described a CRISPR‑Cas9–based approach that selectively targets tumor cells bearing amplified oncogenes. The...
Hims halts compounded GLP‑1 sales after legal pressure — Washington probes
Telehealth firm Hims & Hers pulled a compounded version of Novo Nordisk’s Wegovy after legal pressure from the maker and mounting regulatory scrutiny. Novo Nordisk challenged the product as an...
UniQure pauses Fabry gene‑therapy doses after liver toxicities emerge
UniQure halted mid‑ and high‑dose cohorts in its AAV gene‑therapy trial for Fabry disease after patients experienced dose‑limiting liver toxicities, including grade‑3 transaminase elevations at a...
Eikon prices big IPO — Agomab and SpyGlass bank $350m in Nasdaq wave
Eikon Therapeutics priced an upsized IPO that will raise roughly $381 million to advance its cancer pipeline, marking one of the largest biotech listings of the week. Across the same window,...
Bayer’s Factor XIa pill cuts secondary stroke risk 26% — no extra bleeding
Bayer reported Phase 3 results showing its Factor XIa inhibitor asundexian reduced risk of secondary stroke by 26% without increasing major bleeding. The once‑daily oral candidate delivered a...
Two-pronged pancreatic assault: inflammasome rewires metabolism — epigenetics restores tumor antigenicity
Researchers uncovered complementary molecular strategies in pancreatic ductal adenocarcinoma (PDAC): one study identified the inflammasome protein ASC as a nexus linking innate immune signaling to...
LRRK2 mutation and 3D gut‑brain platform tie gut inflammation to neurodegeneration
A newly reported LRRK2 R1627P mutation markedly amplifies gut inflammation and α‑synuclein aggregation in rat models, implicating a genetically driven gut pathology in early Parkinson’s disease...
Phage plus antibiotic clears drug‑resistant peritonitis in preclinical report
Researchers combined bacteriophage therapy with antibiotics to successfully treat refractory peritoneal dialysis‑associated peritonitis caused by Klebsiella pneumoniae in a Nature Communications...
Dual PLpro and RIPK1 inhibitors show synergistic antiviral activity in mice
Scientists identified small‑molecule inhibitors of SARS‑CoV‑2 papain‑like protease (PLpro) and the host kinase RIPK1 that, when combined, produced potent synergistic antiviral effects in a mouse...
Mussel‑inspired adhesive patch attacks glioblastoma cells
Engineers developed a mussel‑inspired bioadhesive patch designed to localize to glioblastoma margins and deliver cytotoxic payloads that eliminate invasive tumor cells in preclinical models. The...
Sequencing and MRD uptake accelerate: Adaptive raises guidance as Illumina sees clinical consumables growth
Adaptive Biotechnologies projected at least 20% year‑over‑year MRD revenue growth for 2026, driven by adoption of its ClonoSeq minimal residual disease assay, broader blood‑based testing, EMR...
UniQure pauses higher Fabry gene doses — safety signal emerges
UniQure paused mid‑ and high‑dose cohorts in its AAV gene‑therapy study for Fabry disease after patients developed dose‑limiting liver toxicities. Company filings and trial updates show two...
Hims launches Wegovy knockoff — regulators take aim
Telehealth company Hims & Hers moved to market a compounded, oral version of semaglutide marketed as a weight‑loss pill, drawing immediate pushback from originator drugmakers and regulators. Novo...
White House rolls out TrumpRx — early reach looks limited
The White House launched TrumpRx, a direct‑to‑consumer drug‑pricing hub built on technology from GoodRx that displays cash prices for a curated list of medicines. Officials rolled the platform out...
Biotech IPO surge returns — Eikon leads big public raises
Biotech markets saw a cluster of sizable public offerings as Eikon Therapeutics priced an upsized IPO to raise $381 million and peers Agomab Therapeutics and SpyGlass Pharma raised a combined $350...